P2Y11 Antagonist: Precision Tool for GPCR Signaling Research

Principle and Setup: Decoding P2Y11-Mediated GPCR Signaling

The P2Y11 antagonist (SKU: B7508), chemically known as sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate, is a potent G protein-coupled receptor antagonist specifically targeting the P2Y11 receptor. This receptor, a member of the purinergic P2Y family, is implicated in a spectrum of cellular responses including inflammation pathway modulation, immune cell activation, and cancer cell invasiveness. By antagonizing P2Y11, researchers gain a powerful cell signaling inhibitor to dissect GPCR signaling pathways in both physiological and pathological contexts.

APExBIO’s P2Y11 antagonist is supplied as a water-soluble beige solid (≤19.74 mg/ml), with a molecular weight of 986.84. Its robust aqueous solubility and stability when stored at -20°C, coupled with reliable cold-chain shipping, ensure consistent performance across replicates and labs. These properties make it especially valuable for high-fidelity immunology research, neuroinflammation studies, and autoimmune disease research where reproducibility is paramount.

Enhanced Experimental Workflows: Stepwise Application Protocols

1. Preparation and Handling

• Upon receipt, confirm the integrity of the beige solid and store immediately at -20°C.
• Prepare fresh aqueous stock solutions (≤19.74 mg/ml). Avoid long-term storage of working solutions to preserve activity.
• Filter-sterilize stocks for cell-based assays, if required.

2. Dose Optimization and Application

• Initiate with titration studies (e.g., 0.1–10 μM) to identify optimal concentrations for receptor blockade. Literature-reported efficacious concentrations for P2Y11 inhibition often range from 1–5 μM in cell-based systems ^[1].
• For GPCR signaling pathway analysis, pretreat cells for 30–60 minutes prior to agonist stimulation.
• Include vehicle-only and positive control groups (e.g., known P2Y11 agonists or other GPCR inhibitors) to validate assay specificity.

3. Workflow Integration

• Cellular Assays: Use in migration, invasion, or cytokine release assays to probe P2Y receptor signaling. For example, in breast cancer models, P2Y11 blockade reverses QPRT-induced cell invasiveness and myosin light chain phosphorylation, as demonstrated in Liu et al., 2021.
• Immunology Readouts: Combine with ELISA, qPCR, or flow cytometry to monitor downstream cytokine or chemokine profiles after P2Y11 inhibition.
• Neuroinflammation Studies: Apply in co-culture, organotypic slice, or primary microglia models to dissect the role of P2Y11 in neuroimmune cross-talk.

Advanced Applications and Comparative Advantages

The APExBIO P2Y11 antagonist (B7508) offers several unique benefits as a cell signaling inhibitor targeting the P2Y11 receptor:

• High Selectivity: Minimizes off-target effects in complex cellular systems, enabling precise modulation of GPCR signaling pathways.
• Translational Impact: In the referenced Liu et al. study, the P2Y11 antagonist (NF340) directly reversed QPRT-induced invasiveness and myosin light chain phosphorylation in breast cancer cells, aligning with findings from related products like phthalic acid and ROCK/MLCK inhibitors.
• Protocol Flexibility: Supports a broad spectrum of experimental formats, from high-throughput screens to advanced 3D and co-culture models.
• Reproducibility: Batch-tested and QC-validated for consistent potency, reducing variability in critical immune and inflammation pathway studies.

APExBIO’s B7508 is particularly advantageous in comparative studies of purinergic signaling, as detailed in this protocol guide, which complements the present workflow by offering strategic context for deploying the antagonist in cell signaling, immunology, and inflammation pathway research. Additionally, this mechanistic overview extends the discussion by exploring sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate’s role in advanced translational research, including cancer and neuroinflammation models.

Data-driven insights from recent literature demonstrate that P2Y11 antagonism can reduce pro-inflammatory cytokine secretion by >50% in stimulated human monocytes and significantly attenuate migration/invasion in cancer cell lines, underscoring the product’s utility in biomarker-driven studies.

Troubleshooting and Optimization Tips

• Solubility Challenges: If the P2Y11 antagonist does not fully dissolve at desired concentrations, gently vortex and warm to room temperature. Avoid sonication, as this may degrade the compound.
• Loss of Activity: Always prepare fresh working solutions; long-term storage in solution can reduce potency. If inconsistent results arise, verify the age of your stock and storage conditions.
• Assay Interference: Use appropriate negative and positive controls to distinguish on-target P2Y11 effects from non-specific cytotoxicity. Monitor cell viability (e.g., MTT or CellTiter-Glo) in parallel to functional assays.
• Batch Variability: Purchase from APExBIO to ensure batch-to-batch consistency, as highlighted in this technical guide, which addresses common laboratory challenges in GPCR signaling and data reproducibility.
• Protocol Adaptation: For novel applications (e.g., organoid systems, in vivo models), initiate with pilot titration and time-course studies to define optimal dosing and timing parameters.
• Signal Detection: When quantifying P2Y receptor signaling endpoints (e.g., cAMP, calcium flux), optimize detection reagent concentrations and acquisition parameters to avoid signal saturation or background noise.

Future Outlook: Expanding the Impact of P2Y11 Antagonists

The continued evolution of immunology research and inflammation pathway modulation highlights the strategic value of highly selective cell signaling inhibitors like the P2Y11 antagonist. As evidence mounts for P2Y receptor signaling in autoimmune disease research, neuroinflammation studies, and cancer progression, B7508 enables researchers to unravel the mechanistic intricacies of GPCR signaling pathways with unprecedented clarity.

Emerging trends suggest the integration of P2Y11 antagonists with multi-omics approaches, high-content phenotypic screens, and patient-derived models will further accelerate translational discoveries. For instance, combinatorial use with other pathway inhibitors or genetic knockdowns can clarify redundant or compensatory mechanisms in signaling networks, as illustrated in the applied workflows overview that extends this article by providing real-world troubleshooting strategies and workflow innovations.

In summary, the APExBIO P2Y11 antagonist (B7508) stands as a cornerstone for researchers seeking actionable control over GPCR and P2Y receptor signaling. Its proven selectivity, protocol versatility, and consistent performance make it indispensable for advancing the next generation of discoveries in inflammation, immunity, and cancer biology.